Novavax focuses on variant-specific vaccines in expanded deal with South Korean manufacturer
2022-07-20
疫苗紧急使用授权
The rollercoaster ride for Novavax’s Covid-19 vaccine has finally resulted in an emergency use authorization from the FDA. However, as the Omicron variant spreads, the company is turning to a Korean manufacturer to upgrade its capabilities.
The Maryland-based company inked agreements with SK bioscience for the manufacturing and supply of a version of its vaccine that’s specifically designed to protect against Omicron, Novavax announced on Tuesday. SK also committed to manufacturing Novavax’s vaccine in prefilled syringes, though the financial details were not disclosed.
The agreement builds on an existing deal that Novavax and SK struck back in 2021, according to the
Korean news site
T
he
Korea Herald.
SK already manufactures drugs substance for the current vaccine, but soon that will also cover a wide range of Covid-19 variants, including the Omicron BA.5 variant now dominant in the US, Novavax said.
“We are accelerating our clinical program evaluating an Omicron BA.5 component to our vaccine and look forward to continuing to work with SK bioscience as an important manufacturing partner,” Novavax CEO Stanley Erck said.
The Korea Herald reported that the companies’ deal for the supply of prefilled syringes is worth $29.8 million.
“SK bioscience will begin work to enable the manufacturing process for commercial supply of the vaccine in prefilled syringes in 2023,” Novavax said in a statement.
SK has the exclusive commercialization rights for the vaccine in South Korea, and the partners have joint rights in both Vietnam and Thailand.
Novavax finally got over the FDA hurdle last week,
following months of delays
. The company is set to release its first lot in the US soon, according to a
report from
Reuters.
SK has recently been looking to the US for more business.
In January
the company took a stake in the Pennsylvania-based Center for Breakthrough Medicines, investing $350 million of equity financing.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。